journal
MENU ▼
Read by QxMD icon Read
search

Current Hematologic Malignancy Reports

journal
https://www.readbyqxmd.com/read/28913766/computational-modeling-and-treatment-identification-in-the-myelodysplastic-syndromes
#1
REVIEW
Leylah M Drusbosky, Christopher R Cogle
PURPOSE OF REVIEW: This review discusses the need for computational modeling in myelodysplastic syndromes (MDS) and early test results. RECENT FINDINGS: As our evolving understanding of MDS reveals a molecularly complicated disease, the need for sophisticated computer analytics is required to keep track of the number and complex interplay among the molecular abnormalities. Computational modeling and digital drug simulations using whole exome sequencing data input have produced early results showing high accuracy in predicting treatment response to standard of care drugs...
September 14, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28852963/minimal-residual-disease-eradication-in-cml-does-it-really-matter
#2
REVIEW
Srinivas K Tantravahi, Raga S Guthula, Thomas O'Hare, Michael W Deininger
BCR-ABL1 tyrosine kinase inhibitors (TKIs) have improved the prognosis of chronic phase chronic myeloid leukemia (CP-CML) to an extent that survival is largely determined by non-CML mortality. Monitoring for minimal residual disease by measuring BCR-ABL1 messenger RNA is a key component of CML management. CP-CML patients who achieve a stable deep molecular response may discontinue (TKIs) with an ~ 50% chance of entering treatment-free remission (TFR). So far discontinuation of TKIs has largely been limited to clinical trials, but is on the verge of becoming a part of wider clinical practice...
August 29, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28844082/molecular-data-and-the-ipss-r-how-mutational-burden-can-affect-prognostication-in-mds
#3
REVIEW
Aziz Nazha, Rafael Bejar
PURPOSE OF REVIEW: The purpose of this study is to review established prognostic models in myelodysplastic syndromes (MDS) and describe how molecular data can be used to improve patient risk stratification. RECENT FINDINGS: Somatic mutations are common in MDS and are associated with disease features including outcomes. Several recurrently mutated genes have prognostic significance independent of risk stratification tools used in practice. However, this prognostic impact can depend on the clinicogenetic context in which mutations occur...
August 26, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28822058/immune-dysfunction-in-non-hodgkin-lymphoma-avenues-for-new-immunotherapy-based-strategies
#4
REVIEW
Lorenzo Falchi
PURPOSE OF THIS REVIEW: The present review focuses on key aspects of non-Hodgkin lymphoma (NHL) evasion of immune surveillance and how these can be leveraged to devise effective immunotherapy strategies. RECENT FINDINGS: In recent years, significant progress has been made in the field of cancer immunotherapy. In particular, the remarkable clinical results of anti-programmed death (PD)-1/PD-ligand (L)1 antibodies are revolutionizing the treatment approach to multiple solid and hematologic tumors...
August 18, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28822056/patient-reported-outcomes-in-myelodysplastic-syndromes-and-mds-mpn-overlap-syndromes-stepping-onto-the-stage-with-changing-times
#5
REVIEW
Sagar S Patel, Aaron T Gerds
Quality of life (QOL) and symptom burden are important measures captured by patient-reported outcomes (PROs). Myelodysplastic and myelodysplastic/myeloproliferative (MDS/MPN) neoplasm overlap syndromes are notable for significant morbidity and mortality, including a wide spectrum of physical and psychosocial effects. Thus, the development and application of PROs can provide meaningful information to facilitate communication and assist in follow up care. Disease-specific measures can more accurately reflect the full breadth of functional restrictions and symptoms...
August 18, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28822050/nuances-of-morphology-in-myelodysplastic-diseases-in-the-age-of-molecular-diagnostics
#6
REVIEW
Aaron C Shaver, Adam C Seegmiller
Morphologic dysplasia is an important factor in diagnosis of myelodysplastic syndrome (MDS). However, the role of dysplasia is changing as new molecular genetic and genomic technologies take a more prominent place in diagnosis. This review discusses the role of morphology in the diagnosis of MDS and its interactions with cytogenetic and molecular testing. Recent changes in diagnostic criteria have attempted to standardize approaches to morphologic diagnosis of MDS, recognizing significant inter-observer variability in assessment of dysplasia...
August 18, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28819882/novel-immunotherapies-for-multiple-myeloma
#7
REVIEW
Mattia D'Agostino, Mario Boccadoro, Eric L Smith
PURPOSE OF REVIEW: The treatment landscape of multiple myeloma is rapidly changing; however, despite improvement in patients' survival, it still remains a largely incurable disease. One hallmark of myeloma is substantial immune dysfunction leading to an increased infection rate and the inability of immune surveillance to detect neoplastic cells. Here, we critically analyze clinical approaches to harness the immune system to overcome this defect with a focus on antibody based and adoptive cellular therapies...
August 18, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28780614/targeting-immune-system-alterations-in-hodgkin-lymphoma
#8
REVIEW
Natalie S Grover, Barbara Savoldo
PURPOSE OF REVIEW: This review discusses novel immunotherapeutic approaches to treat Hodgkin lymphoma (HL), specifically PD-1 inhibitors and cellular immunotherapy. RECENT FINDINGS: PD-1 inhibitors have shown promising results in the treatment of relapsed or refractory HL, leading to FDA approval of nivolumab and pembrolizumab, although complete remissions are rare. Chimeric antigen receptor T cells directed against CD30 have been investigated with preliminary clinical trials showing minimal toxicities and some responses in heavily pre-treated patients with HL...
August 5, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28762038/considerations-in-t-cell-therapy-product-development-for-b-cell-leukemia-and-lymphoma-immunotherapy
#9
REVIEW
Andrew D Fesnak, Patrick J Hanley, Bruce L Levine
Based on laboratory and clinical research findings and investments in immunotherapy by many institutions in academia, government-funded laboratories, and industry, there is tremendous and deserved excitement in the field of cell and gene therapy. In particular, understanding of immune-mediated control of cancer has created opportunities to develop new forms of therapies based on engineered T cells. Unlike conventional drugs or biologics, the source material for these new therapies is collected from the patient or donor...
July 31, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28735365/an-update-on-the-use-of-immunotherapy-in-the-treatment-of-lymphoma
#10
REVIEW
Thomas U Marron, Matko Kalac, Joshua Brody
PURPOSE OF REVIEW: Throughout the field of oncology, immunotherapy is moving further towards the first-line setting, and there is encouraging data for the use of these novel therapies in the management of lymphomas, utilizing treatments approved for both solid and hematologic malignancies. Herein, we review promising advances in this rapidly moving field from the past year. RECENT FINDINGS: In the last year, we have seen promising clinical data on engineered antibody therapies for the treatment of lymphomas, as well as further optimization of engineered antibody fragments fused onto linkers or chimeric T cell receptors, both of the modalities capable of transforming non-specific T cells into tumor-specific, serial killer cells...
July 22, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28656487/chimeric-antigen-receptor-therapy-in-acute-lymphoblastic-leukemia-clinical-practice
#11
REVIEW
Marlise R Luskin, Daniel J DeAngelo
Over half of patients diagnosed with B-cell acute lymphoblastic leukemia (ALL) develop relapsed or refractory disease. Traditional chemotherapy salvage is inadequate, and new therapies are needed. Chimeric antigen receptor (CAR) T cell therapy is a novel, immunologic approach where T cells are genetically engineered to express a CAR conferring specificity against a target cell surface antigen, most commonly the pan-B-cell marker CD19. After infusion, CAR T cells expand and persist, allowing ongoing tumor surveillance...
June 27, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28639084/early-palliative-care-for-patients-with-hematologic-malignancies-is-it-really-so-difficult-to-achieve
#12
REVIEW
Thomas W LeBlanc, Eric J Roeland, Areej El-Jawahri
Evidence points to many benefits of "early palliative care," the provision of specialist palliative care services upstream from the end of life, to improve patients' quality of life while living with a serious illness. Yet most trials of early palliative care have not included patients with hematologic malignancies. Unfortunately, patients with hematologic malignancies are also known to have substantial illness burden, poor quality of life, and aggressive care at the end of life, including a greater likelihood of dying in the hospital, receiving chemotherapy at the end of life, and low hospice utilization, compared to patients with solid tumors...
June 21, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28626849/equal-treatment-and-outcomes-for-everyone-with-multiple-myeloma-are-we-there-yet
#13
REVIEW
Sikander Ailawadhi, Kirtipal Bhatia, Sonikpreet Aulakh, Zahara Meghji, Asher Chanan-Khan
Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics...
June 19, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28573497/therapeutic-options-for-aggressive-t-cell-lymphomas
#14
REVIEW
Jennifer K Lue, Anna Kress, Jennifer E Amengual
T-cell lymphomas (TCL) are a rare, heterogeneous group of non-Hodgkin lymphomas associated with very poor prognosis with standard cytotoxic chemotherapy. Epigenetic-based therapy, such as with histone deacetylase inhibitors, was initially discovered to be efficacious in TCL. In recent years, our understanding of the mechanisms driving T-cell lymphomagenesis has validated the use of epigenetic-based drugs and has also led to the development of novel agents with promising efficacy in pre-clinical and early clinical trials...
June 1, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28573496/patient-and-caregiver-adjustment-to-hematopoietic-stem-cell-transplantation-a-systematic-review-of-dyad-based-studies
#15
REVIEW
Shelby Langer, Christine Lehane, Jean Yi
PURPOSE OF REVIEW: The aims of this study were to identify and systematically evaluate studies published from 2005-2017 that took a dyadic approach to assessing or intervening upon hematopoietic cell transplant (HCT) recipients and their informal caregivers. RECENT FINDINGS: Our search yielded 20 studies. Regarding sample demographic characteristics, most participants were Caucasian and most caregivers were related to the patient by marriage. Regarding design characteristics, 18 studies were quantitative and two were qualitative; five were cross-sectional, ten were longitudinal, one was experimental, and four were interventional...
June 1, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28540671/multidisciplinary-management-of-mycosis-fungoides-s%C3%A3-zary-syndrome
#16
REVIEW
Sara Berg, Jennifer Villasenor-Park, Paul Haun, Ellen J Kim
PURPOSE OF REVIEW: Diagnosis and management of mycosis fungoides and Sézary syndrome (MF/SS) require accurate clinicopathological correlation and a multidisciplinary approach. We reviewed major advances in the field regarding diagnostic and prognostic tools as well as skin-directed therapies (SDTs) and systemic agents for MF/SS published in the past 2 years. RECENT FINDINGS: Improved technology (T-cell receptor high-throughput sequencing) and increased multicenter collaboration (Cutaneous Lymphoma International Consortium) have led to diagnostic/prognostic advances...
June 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28497317/role-of-radiation-therapy-in-the-treatment-of-hodgkin-lymphoma
#17
REVIEW
Victor J Gonzalez
Radiation therapy has historically been the pillar of curative treatment for Hodgkin lymphoma (HL). With improved efficacy of systemic therapy and the ever-increasing recognition of treatment-related morbidity in long-term survivors, the role of radiotherapy has evolved significantly. Modern combined modality therapy (CMT) with multi-agent chemotherapy followed by involved site radiation therapy (ISRT) to initially involved sites of disease remains the gold standard for the majority of patients with HL. Reduction of long-term treatment-related toxicity has become the major driver in clinical trial design for early-stage HL while improved disease-specific survival remains the goal in patients with more advanced and unfavorable disease...
June 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28488185/where-do-the-new-drugs-fit-in-for-relapsed-refractory-hodgkin-lymphoma
#18
REVIEW
Niloufer Khan, Alison J Moskowitz
The standard approach for relapsed or refractory (rel/ref) Hodgkin lymphoma (HL) following frontline treatment failure is salvage therapy followed by consolidation with high-dose therapy and autologous stem cell transplant (HDT/ASCT). While this overall treatment paradigm has been in place for several decades, recent studies have aimed to improve the efficacy and tolerability of salvage therapies by incorporating newer drugs, such as brentuximab vedotin (BV) and checkpoint inhibitors. Following HDT/ASCT, survival is improved due to the availability of BV and the checkpoint inhibitors, nivolumab and pembrolizumab; however, for patients responding to checkpoint inhibition, the appropriate length of treatment and the role of allogeneic stem cell transplant are unclear...
June 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28478586/a-review-of-autologous-stem-cell-transplantation-in-lymphoma
#19
REVIEW
Umar Zahid, Faisal Akbar, Akshay Amaraneni, Muhammad Husnain, Onyee Chan, Irbaz Bin Riaz, Ali McBride, Ahmad Iftikhar, Faiz Anwer
PURPOSE OF REVIEW: Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20-30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. RECENT FINDINGS: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL...
June 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28470380/the-management-of-lymphoma-in-the-setting-of-pregnancy
#20
REVIEW
Chelsea C Pinnix, Therese Y Andraos, Sarah Milgrom, Michelle A Fanale
The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors, of which the most influential are the trimester at diagnosis, the stage, and aggressiveness of the disease and the presence of life-threatening symptoms. Recent data suggest that deferral of therapy until after the first trimester is desirable if it is perceived that postponement of therapy will not compromise maternal outcome...
June 2017: Current Hematologic Malignancy Reports
journal
journal
41232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"